# Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI

> **NCT02859727** · PHASE2,PHASE3 · TERMINATED · sponsor: **Pharming Technologies B.V.** · enrollment: 37 (actual)

## Conditions studied

- Activated PI3Kdelta Syndrome (APDS); PASLI Disease

## Interventions

- **DRUG:** CDZ173

## Key facts

- **NCT ID:** NCT02859727
- **Lead sponsor:** Pharming Technologies B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-09-08
- **Primary completion:** 2025-01-30
- **Final completion:** 2025-01-30
- **Target enrollment:** 37 (ACTUAL)
- **Why stopped:** All participant have transitioned to commercial product or compassionate use.
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02859727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02859727, "Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02859727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*